BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17011205)

  • 21. Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice.
    Schilling G; Savonenko AV; Coonfield ML; Morton JL; Vorovich E; Gale A; Neslon C; Chan N; Eaton M; Fromholt D; Ross CA; Borchelt DR
    Exp Neurol; 2004 May; 187(1):137-49. PubMed ID: 15081595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minocycline in phenotypic models of Huntington's disease.
    Bantubungi K; Jacquard C; Greco A; Pintor A; Chtarto A; Tai K; Galas MC; Tenenbaum L; Déglon N; Popoli P; Minghetti L; Brouillet E; Brotchi J; Levivier M; Schiffmann SN; Blum D
    Neurobiol Dis; 2005 Feb; 18(1):206-17. PubMed ID: 15649711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease.
    Vamos E; Voros K; Vecsei L; Klivenyi P
    Biomed Pharmacother; 2010 Apr; 64(4):282-6. PubMed ID: 19932584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of brain-derived neurotrophic factor in astrocytes - Beneficial effects of glatiramer acetate in the R6/2 and YAC128 mouse models of Huntington's disease.
    Reick C; Ellrichmann G; Tsai T; Lee DH; Wiese S; Gold R; Saft C; Linker RA
    Exp Neurol; 2016 Nov; 285(Pt A):12-23. PubMed ID: 27587303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease.
    Andreassen OA; Dedeoglu A; Ferrante RJ; Jenkins BG; Ferrante KL; Thomas M; Friedlich A; Browne SE; Schilling G; Borchelt DR; Hersch SM; Ross CA; Beal MF
    Neurobiol Dis; 2001 Jun; 8(3):479-91. PubMed ID: 11447996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease.
    Lee ST; Chu K; Park JE; Kang L; Ko SY; Jung KH; Kim M
    Brain Res; 2006 Nov; 1118(1):199-207. PubMed ID: 16959224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.
    Ferrante RJ; Andreassen OA; Dedeoglu A; Ferrante KL; Jenkins BG; Hersch SM; Beal MF
    J Neurosci; 2002 Mar; 22(5):1592-9. PubMed ID: 11880489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.
    Ginés S; Bosch M; Marco S; Gavaldà N; Díaz-Hernández M; Lucas JJ; Canals JM; Alberch J
    Eur J Neurosci; 2006 Feb; 23(3):649-58. PubMed ID: 16487146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of interleukin-1 type 1 receptor enhances the accumulation of mutant huntingtin in the striatum and exacerbates the neurological phenotypes of Huntington's disease mice.
    Wang CE; Li S; Li XJ
    Mol Brain; 2010 Nov; 3():33. PubMed ID: 21044321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alleviation of Huntington pathology in mice by oral administration of food additive glyceryl tribenzoate.
    Dutta D; Majumder M; Paidi RK; Pahan K
    Neurobiol Dis; 2021 Jun; 153():105318. PubMed ID: 33636386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased calbindin-D28k immunoreactivity in striatal projection neurons of R6/2 Huntington's disease transgenic mice.
    Sun Z; Wang HB; Deng YP; Lei WL; Xie JP; Meade CA; Del Mar N; Goldowitz D; Reiner A
    Neurobiol Dis; 2005 Dec; 20(3):907-17. PubMed ID: 15990326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease.
    Boussicault L; Alves S; Lamazière A; Planques A; Heck N; Moumné L; Despres G; Bolte S; Hu A; Pagès C; Galvan L; Piguet F; Aubourg P; Cartier N; Caboche J; Betuing S
    Brain; 2016 Mar; 139(Pt 3):953-70. PubMed ID: 26912634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models.
    Sontag EM; Lotz GP; Agrawal N; Tran A; Aron R; Yang G; Necula M; Lau A; Finkbeiner S; Glabe C; Marsh JL; Muchowski PJ; Thompson LM
    J Neurosci; 2012 Aug; 32(32):11109-19. PubMed ID: 22875942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroprotective effects of probenecid in a transgenic animal model of Huntington's disease.
    Vamos E; Voros K; Zadori D; Vecsei L; Klivenyi P
    J Neural Transm (Vienna); 2009 Sep; 116(9):1079-86. PubMed ID: 19551467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease.
    Zádori D; Geisz A; Vámos E; Vécsei L; Klivényi P
    Pharmacol Biochem Behav; 2009 Nov; 94(1):148-53. PubMed ID: 19698736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice.
    Stack EC; Dedeoglu A; Smith KM; Cormier K; Kubilus JK; Bogdanov M; Matson WR; Yang L; Jenkins BG; Luthi-Carter R; Kowall NW; Hersch SM; Beal MF; Ferrante RJ
    J Neurosci; 2007 Nov; 27(47):12908-15. PubMed ID: 18032664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of minocycline efficiency in genetic models of Huntington's disease.
    Mievis S; Levivier M; Communi D; Vassart G; Brotchi J; Ledent C; Blum D
    Neuromolecular Med; 2007; 9(1):47-54. PubMed ID: 17114824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preconditioning mesenchymal stem cells with the mood stabilizers lithium and valproic acid enhances therapeutic efficacy in a mouse model of Huntington's disease.
    Linares GR; Chiu CT; Scheuing L; Leng Y; Liao HM; Maric D; Chuang DM
    Exp Neurol; 2016 Jul; 281():81-92. PubMed ID: 27085395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.
    Wang SE; Lin CL; Hsu CH; Sheu SJ; Chien CT; Wu CH
    Drug Des Devel Ther; 2015; 9():887-900. PubMed ID: 25733809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease.
    McBride JL; Ramaswamy S; Gasmi M; Bartus RT; Herzog CD; Brandon EP; Zhou L; Pitzer MR; Berry-Kravis EM; Kordower JH
    Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9345-50. PubMed ID: 16751280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.